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1. Biological markers of oxidative stress
Oxidative stress is defined as an imbalance of antioxidants and
pro-oxidants in favour of the latter, potentially leading to damage
[5,6]. On the other hand, Jones [6] defines oxidative stress as a
disruption of redox signalling and/or control of molecular damage.
The reactive oxygen species (ROS) and reactive-nitrogen species
(RNS) have function in redox signalling and are produced as by-
products of normal metabolic process in all aerobic organisms, at
very low concentrations in cells [6,7]. Increased oxidative/nitro-
sative stress is characterized by inadequate cellular antioxidant
defences to efficiently inactivate the overproduced ROS and RNS. A
major consequence of oxidative/nitrosative stress is the damage of
nucleic acid bases, proteins, lipids (including phospholipids) and
carbohydrates [7,8]. This damage can compromise cell health and
viability, as well as induce a variety of cellular responses like cell
death by necrosis or apoptosis [8].
The molecules modified by interactions with ROS (including
RNS) in the microenvironment, and those changed in response to
increased redox stress are considered biomarkers of oxidative
stress [2]. Fig. 1 represents a schematization of biomarkers of
oxidative stress, which can be classified as molecules that are
modified by interactions with ROS in the microenvironment, and
molecules of the antioxidant system that change in response to
increased redox stress.
A very promising approach for the assessment of oxidative
stress is the detection of nitrated tyrosine (Tyr) residues in proteins
[9].2. Nitrotyrosine in physiological conditions
Tyr (4-hydroxyphenylalanine) is a non-essential amino acid and
an element of the aromatic amino acids group. Most proteins found
in nature contain Tyr residues in their composition, with an average
abundance of about 3e4 mol % [10,11]. Tyr is moderately hydro-
philic, which is explained by its hydrophobic aromatic benzene ring
carrying a hydroxyl group [12,13]. As a result, Tyr is frequently
surface-exposed in proteins allowing further modification, namely
nitration. The nitration of Tyr residues in proteins is associated with
nitrosative stress, resulting in the formation of 3-nitrotyrosine (3-
NT) or other Tyr-nitrated proteins residues [10,14].
When RNS reacts with L-tyrosine and protein-associated Tyr,
free 3-nitro-L-tyrosine and protein-associated 3-nitro-L-tyrosine
are formed (Fig. 2) [1]. 3-NT [(2-amino-3-(4-hydroxy-3-
nitrophenyl) propanoic acid)] is the result of a post-translational
modification in proteins carried by RNS, such as nitric oxide (NO),
derived oxidants (e.g., peroxynitrite (ONOO) and peroxynitrous
acid (ONOOH)) and nitrogen dioxide radicals (NO2). It is formed
after the substitution of a hydrogen by a nitro group (NO2) in the
ortho position of the phenolic ring of the Tyr residues [10,11,13,14].
The protein tyrosine nitration (PTN) is a stable post-
translational modification process and does not happen
randomly. The abundance of protein or Tyr residues cannot predict
whether they will be the target of PTN. Furthermore, not all Tyrresidues in a protein are available for nitration, which may depend
on their accessibility to the solvent [10,15]. For instance, although
the human serum albumin (HSA), a protein most abundantly found
in plasma, contains 18 Tyr residues, an in vitro study showed that
only two of its Tyr residues are predominantly susceptible to
nitration [14,16].
The wide range of chemical and structural modifications of
proteins, such as modifications affecting signal transduction path-
ways and cellular processes, are responsible for high levels of RNS
and antioxidant enzymatic systems [17,18].
3. Metabolism of nitric oxide and its role in 3-nitrotyrosine
biosynthesis
Themajor pathway for NOmetabolism is the stepwise oxidation
to nitrite and nitrate [3]. In biological fluids or buffers, NO systems
are almost completely oxidized to nitrite (NO2 ), a biologically inert
metabolite of NO oxidation [19].
TheoxidationofNObymolecularoxygen(O2),physicallydissolved
in biological systems, originates NO2 (nitrogen dioxide), N2O3 (dini-
trogen trioxide) and NO2 (reactions 1, 2 and 3). N2O3 is characterized
as a potent nitrosating agent, since it gives rise to the formation of the
nitrosonium ion (NOþ). On the other hand, NO and NO2 are rapidly
oxidized to nitrate ðNO3 Þ in blood [3,14].
2NOþ O2/2NO2 (1)
2NOþ 2NO2/2N2O3 (2)
2N2O3 þ 2H2O/4NO2 þ 4Hþ (3)
In erythrocytes, NO directly and rapidly reacts with O2 bound to
haemoglobin (i.e. oxyhemoglobin (Hb[Fe2þ]O2)), to form the
chemically quite inert anion NO3 (reaction 4).
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Other proposed mechanism for NO3 formation is via oxidation
of NO2 (derived from NO autoxidation e reaction 3) by certain
oxyhemoproteins (Hb[Fe2þ]O2), such as oxyhemoglobin or oxy-
myoglobin (reactions 5 and 6) [3].
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Concerning free radical superoxide ðO2 Þ, this may promptly
interact with NO to produce the peroxynitrite anion (ONOO) (re-
action 7) [20,21].
·NOþ O$2 /ONOO (7)
Fig. 1. Formation pathways of selected biomarkers of oxidative stress. Oxidized Low-Density Lipoprotein (Ox-LDL). Protein oxidation markers: protein nitration (3-nitrotyrosine).
Oxidative DNA damage biomarkers: 8-hydroxy-20-deoxyguanosine (8-OHdG). Antioxidant enzymes and molecules: superoxide dismutase, catalase, glutathione peroxidase,
oxidized glutathione, total antioxidant capacity. GS, glutathione; reduced glutathione (GSH); oxidized glutathione (GSSG); PUFA, polyunsaturated fatty acids. Nicotinamide adenine
dinucleotide phosphate (NADPH), nitric oxide synthase (NOS), mieloperoxidase (MPO). Adapted from Ho et al. [2] and Shah et al. [4].Peroxynitrite is the extremely reactive conjugate base of per-
oxynitrous acid (ONOOH) (reaction 8) [3,14].
4ONOO þ 4Hþ44ONOOH/2NO3 þ 2NO2 þ O2 þ 4Hþ (8)
In biological systems, ONOO/ONOOH system is a very strong
oxidant and a potent nitrating agent, thus it has been implicated as
a culprit in many diseases [22]. Peroxynitrite promotes nitration
and hydroxylation in different bioorganic molecules, including
proteins, lipids, thiols, sulfhydryl groups, DNA bases, and prefer-
entially nitrates Tyr residues of protein or non-protein origins
[23,24]. Peroxynitrite reacts whit CO2 to yield a nitro-
soperoxycarbonate anion ðONOOCO2 Þ that undergoes a fast ho-
molysis to NO2 and carbonate radicals ðCO3 Þ (reaction 9) [18,23,25].
ONOOe þ CO2/ONOOCO2/NO2 þ CO3 (9)
The in vivo production of ONOO leads to the nitration of Tyr
residues in proteins, forming 3-NT, although it does not directly
react with Tyr. Instead, it forms secondary radicals, such as COe3 ,NO2 and oxo-metal complexes, which are indeed responsible for
protein Tyr oxidation and nitration. The mechanism of Tyr nitration
in biological systems is a two-step process (reactions 10 and 11)
[23].
TyrHþ COe3 /Tyr þ HCO3 (10)
Tyr þ NO2/Tyr NO2 (11)
Moreover, 3-NT may be generated through multiple pathways
(Fig. 3). Tyr can be nitrated by peroxidase (or heme/hemoprotein)
through the in vivo hydrogen peroxide-dependent oxidation of
nitrite to form NO2 (reactions 12e14) [3,18,26].
H2O2 þ peroxidaseðhemeÞ/oxidantðporphyrin radicalÞ (12)
Oxidantþ NO2/NO2 (13)
Fig. 2. Nitration of L-tyrosine to 3-nitro-L-tyrosine (Adapted from Tsikas and Caidahl [1]).
Fig. 3. Multiple pathways for the formation of 3-nitrotyrosine (Adapted from Bryan and Grisham [3]).2NO2 þ Try/3 NT (14)4. Association between 3-nitrotyrosine and disease
Several physiological and pathological conditions have been
associated with increased nitration of proteins [15,21]. Table 1
shows the 3-NT concentration range usually found in both
healthy and pathological states, as determined by different
Table 1
3-NT concentration ranges found in different biological samples from both healthy and pathological states, as determined by different methodologies.
Reference Sample (mean age ± years) Biological sample Method Concentration 3-NT
S€oderling et al.
[54]
12 Healthy non-smoking volunteers (43 ± 9) Plasma GC/NCI-MS/MS 0.74 ± 0.31 nMa
Tsikas et al.
[55]
10 Healthy volunteers (51 ± 10) Plasma GC tandem MS 1.149 ± 0.73 nMa
6 Healthy volunteers (25 ± 3) Plasma GC tandem MS 2.677 ± 1.540 nMa
10 Healthy volunteers (51 ± 10) Plasma GC-MS 4.46 ± 4.49 nMa
6 Healthy volunteers (25 ± 3) Plasma GC-MS 5.447 ± 2.783 nMa
Zhang et al.
[56]
20 Healthy non-smoking volunteers (41.2) Plasma LC-MS/MS 4.54 ± 2.75 nMa
18 Healthy smokers (42.0) Plasma LC-MS/MS 17.42 ± 11.6 nMa
Radabaugh
et al. [57]
40 Healthy volunteers Plasma LCeMS/MS 224e962 pg/mL (0.99
e4.2 nM)b
Misko et al.
[39]
143 Healthy volunteers Plasma Immunoaffinity two-
dimensional LC-MS/MS
536.4 pg/mL (2.49 nM)b
174 Osteoarthritis patients Plasma Immunoaffinity two-
dimensional LC-MS/MS
704.1 pg/mL (3.11 nM)b
Pourfarzam
et al. [32]
50 Patients with no history of cardiac diseases (58.9 ± 10.3) Plasma HPLC-fluorescence detector
470 nm
4.4 ± 1.8 nMa
50 Stable CAD patients (61.2 ± 11.23) Plasma HPLC-fluorescence detector
470 nm
12.8 ± 3.9 nMa
50 Unstable CAD patients (59.9 ± 10.45) Plasma HPLC-fluorescence detector
470 nm
14.8 ± 4.8 nMa
Sun et al. [26] 70 Healthy Chinese volunteers Plasma Sandwich ELISA 7.9 ± 7 nmol/Lb
Radabaugh
et al. [57]
131 Healthy volunteers Serum LCeMS/MS 179e1540 pg/mL (0.79
e6.8 nM)b
Khan et al.
[58]
25 Non-smoking healthy female volunteers (age 24e50) Serum Sandwich ELISA 1.1 ± 0.81 mMb
24 Systemic lupus erythematosus patients (age 18e50) Serum Sandwich ELISA 96.52 ± 21.12 mMb
Tsikas et al.
[59]
10 Healthy volunteers (36.5 ± 7.2) Urine GCetandem MS 8.4 ± 10.4 nM
Radabaugh
et al. [57]
8 Healthy volunteers Urine LCeMS/MS 63.5e751 pg/mL (0.28
e3.32 nM)b
Ryberg et al.
[60]
19 Patients without history or symptoms/signs of psychiatric, neurological,
malignant or systemic disorders
Cerebrospinal
fluid
GC/NCI-MS/MS 0.35 ± 0.019 nMa
17 Alzheimer's disease patients Cerebrospinal
fluid
GC/NCI-MS/MS 0.44 ± 0.031 nMa
14 Amyotrophic lateral sclerosis patients Cerebrospinal
fluid
GC/NCI-MS/MS 0.38 ± 0.034 nMa
Radabaugh
et al. [57]
35 Healthy volunteers Cerebrospinal
fluid
LCeMS/MS 335e5730 pg/mL (1.48
e25.33 nM)b
Seven et al.
[61]
15 Volunteers with normal pressure hydrocephalia Cerebrospinal
fluid
ELISA based on the sandwich 573.54 ± 142.86 nM
Seven et al.
[61]
20 Relapsing remitting multiple sclerosis patients before methyl
prednisolone therapy
Cerebrospinal
fluid
ELISA based on the sandwich 927.89 ± 244.84 nM
L€arstad et al.
[62]
10 Healthy subjects (46 ± 2.6) Exhaled breath
condensate
GC/NICI/tandem MS 31 pMa
8 Asthma patients (49 ± 5.1) Exhaled breath
condensate
GC/NICI/tandem MS 31pMa
Radabaugh
et al. [57]
40 Healthy volunteers Synovial fluid LCeMS/MS 54.4e822 pg/mL (0.24
e3.63 nM)b
Ueshima et al.
[63]
5 Chronic obstructive pulmonary disease patients (71.6 ± 2.4) Sputum HPLC-ECD 0.55 ± 0.15 pmol/mLb
5 Chronic obstructive pulmonary disease patients (71.6 ± 2.4) Saliva HPLC-ECD 0.02 ± 0.01 pmol/mLb
GC/NCI-MS/MS, Gas chromatography/negative chemical ionization - mass spectrometry/mass spectrometry; GC tandemMS, Gas chromatography tandemmass spectrometry;
GC-MS, Gas chromatography - mass spectrometry; LCeMS/MS, Liquid chromatography - mass spectrometry/mass spectrometry; HPLC, High Performance Liquid Chroma-
tography; ELISA, Enzyme-Linked Immunosorbent Assay; ECD, electrochemical.
a Free 3-NT.
b Total 3-NT.methods (discussed in detail in the following sections) and bio-
logical samples. According to Table 1, 3-NT levels in pathological
conditions are slightly higher in comparison with basal levels in
healthy individuals. This observation is in fact valid for several
biological specimens, regardless the quantification method used.
Among the pathological conditions, there is a wide range of
cardiovascular diseases, such as myocardial inflammation, heart
failure and arteriosclerosis [5,27e30]. For instance, Shishehbor
et al. [31] and Poufarzam et al. [32] demonstrated that 3-NT plasma
levels are elevated in coronary artery disease (CAD) patients.
Regarding atherosclerosis, it was found that atherosclerotic arteries
have higher 3-NT levels than non-atherosclerotic blood vessels
[33]. Furthermore, there is also evidence of an accumulation of 3-
NT during atherogenesis [34].
In addition, diseases associated with immunological reactionsappear to be connected at a very high degree with the increased
formation of Tyr-nitrated proteins, such as asthma [35], systemic
sclerosis [36], renal complications [4], inflammatory bowel disease
[37], septic shock [38], rheumatoid arthritis and joint injury [39,40].
In relation to asthma, 3-NT expressionwas found to be increased in
several asthmatic epithelial cells and essentially in asthmatic chil-
dren [35,41]. Concerning systemic sclerosis, Shimizu et al. [36]
suggested that serum 3-NT levels are significantly increased in
systemic sclerosis patients compared to healthy controls. Regarding
inflammatory bowel diseases, such as ulcerative colitis, the 3-NT
expression is substantially increased in the inflamed colonic mu-
cosa [37].
Furthermore, some neurological diseases and psychiatric dis-
orders are also associated with an increased level of nitrated pro-
teins. For example, Parakh et al. [42] reported that nitrated proteins
and high levels of 3-NT have been detected in cases of amyotrophic
lateral sclerosis. Conversely, Mendonça et al. [43] demonstrated
that 3-NT was expressed in both amyotrophic lateral sclerosis and
control samples, with no significant difference between them.
Moreover, Dietrich-Muszalska et al. [44] considered that the
amount of 3-NT in plasma proteins may be important indicators of
in vivo protein damage in schizophrenia. Besides, high levels of 3-
NT have also been associated with other pathological conditions,
such as Alzheimer's disease [45], Parkinson's disease [46], autism
[47] and myalgic encephalomyelitis/chronic fatigue syndrome [48].
Other diseases are associated with increased protein nitration.
Shu et al. [49] demonstrated that 3-NT levels in plasma samples
from patients with classical Fabry disease were about six-fold
higher compared with age- and gender-matched controls. The 3-
NT levels are also significantly increased in diabetic patients
[5,50], especially in patients with diabetic nephropathy [51] or
diabetic patients with microvascular complications [52]. Regarding
Chagas disease, Dhiman et al. [53] considered that 3-NT-modified
proteins is an important phase in the pathophysiology of such
disease, and might be useful biomarkers of disease as well. More-
over, Shah et al. [4] demonstrated that 3-NT levels were increased
in plasma and serum of patients with systemic lupus
erythematosus.
5. Quantification of 3-nitrotyrosine in biological samples
Since 3-NT was suggested as a biomarker of nitrosative stress, a
substantial effort has been made to develop analytical methods
that can be applied to biological samples [64]. Accurate quantifi-
cation of substances present in biological samples at very low
concentrations is, indeed, a complex task, and the particular case of
3-NT requires special concerns [1].
3-NT has been detected in several biological tissues and fluids
including plasma, serum, urine, cerebrospinal fluid, synovial fluid,
tissue samples and other biological samples [57]. Recently, Mergola
et al. [65] developed for the first time the synthesis of a highly
selective molecularly imprinted polymer (MIP) used as solid-phase
extraction (SPE) sorbent for pre-concentration of 3-NT and the
selective clean-up from biological sample. The results obtained
suggest that this polymer can be used as an active site in a sensor so
that the analyte can be directly identified in the urine of patients,
where it is normally present at very low concentrations.
A common approach for 3-NT quantification is the prior cleav-
age of peptide bonds in order to release the free amino acids from
proteins in fluids or tissues. This cleavage may be achieved by acid
hydrolysis or enzymatic digestion [14,57,66]. Delatour et al. [66]
compared both methods in terms of the reliability of the 3-NT
measurement, providing evidence that acid hydrolysis leads to
more reliable results. However, Radabaugh, et al. [57] pointed out
that a prior acid hydrolysis step is more prone to artifact formation
in comparison with enzymatic digestion.
Regarding quantification of 3-NT, the first approaches used
different immunological methods. In fact, a large part of studies on
quantification of 3-NT in biological samples has been performed
using antibody-based methods, namely immunohistochemistry
and western blot [13].
5.1. Immunochemical methods
5.1.1. Enzyme-linked immunosorbent assay
ELISA (enzyme-linked immunosorbent assay) is based on the
basic immunology concept of the binding properties of an antibody
to its specific antigen. From a general point of view, this method
employs enzyme-labelled antigens and antibodies to detect a wide
variety of compounds. The antigen-antibody complex is furtherbound by a secondary enzyme-coupled antibody, followed by the
addition of a chromogenic substrate which yields a visible colour
change or fluorescence, allowing the quantification of the com-
pound [67]. One of the main advantages of ELISA technology is that
it allows the simultaneous determination of standards and samples.
Moreover, it does not require complex sample preparation steps
[67].
Regarding 3-NT quantification, there is a wide variety of ELISA-
based methods for this purpose, namely indirect, competitive,
sandwich-ELISA and ELISA microarrays [68,69]. Table 2 lists some
ELISA assays for the analysis of 3-NT in different biological
specimens.
One of the first ELISA methods for the analysis of nitrated pro-
teins in biological fluids was based upon a competitive model [72].
More recently, Safinowski et al. [9] performed a comparison of the
performance of different commercially available immunoassays for
3-NT analysis, and concluded that all of them did not provide
reliable results. They also concluded that the sandwich-based ELISA
assay exhibited the worst performance, probably due to the low
concentration levels of 3-NT in almost all investigated samples.
ELISA requires at least two 3-NT residues for the capture and
detection antibody and, in this sense, the sandwich ELISA measures
only protein associated-3-NT [9,26,69]. Actually, the poor perfor-
mances exhibited by different ELISA can be due to different rea-
sons: (i) the antibodies may reveal some nonspecific binding; (ii) 3-
NT may not be totally accessible to the antibody in some protein
sites; and (iii) monoclonal and polyclonal antibodies used by these
methods may exhibit cross-reactivity with other compounds pre-
sent in biological samples [73].
Regarding microarray-ELISA assays, one of their main advan-
tages is that they use various physically separated capture anti-
bodies (in isolated spots), allowing an efficient way for measuring
low levels of the analyte [68].
5.2. Chromatographic methods
Chromatography is a powerful analytical technique, and is
widely available in different laboratory settings nowadays [74]. This
technique is generally composed by two primary components:
mobile phase and stationary phase [75].
Table 3 shows chromatography classifications according to the
mobile and stationary phases used.
5.2.1. Liquid chromatography methods using ultraviolet,
fluorescence and electrochemical detection
Liquid chromatography (LC) is one of the most extensively used
methods for the determination of 3-NT (Table 4). Several different
detectors have been employed, such as ultra-violet (UV), electro-
chemical (ECD), diode-array (DAD) andmass spectrometry (MS) [14].
HPLC (High Performance Liquid Chromatography) is a chro-
matographic technique that can separate a mixture of compounds,
and is used in biochemistry and analytical chemistry to separate,
identify, quantify and purify the active compounds of a mixture
[75]. The principle behind this technique relies on the injection of
the sample into a column that holds packing material (stationary
phase), with further pumping of the mobile phase(s) through the
column, at high pressure, and the detection through the retention
times exhibited by the molecules [76].
HPLC is the standard technique for analysing amino acids, being
the technique used by most laboratories [13]. One of the first
chromatographic methods for quantifying 3-NT uses isocratic
reversed phase HPLC and UV absorbance detection at 274 nm, as
first reported by Kaur and Halliwell [77]. This HPLC-based method
uses column with C-18, eluent (500 mM KH2PO4eF3PO4 with 10%
methanol (v/v)), an acidic mobile phase (pH 3.01), and with a
Table 2
ELISA assays for the analysis of 3-NT in different biological specimens.
Compound Biological specimen ELISA type Sensitivity/Detection range/Standard curve/LOD/LOQ for 3-NT
3-NT [70] Bronchoalveolar lavage Sandwich ELISA 2.0 nmol/L (Sensitivity)
3-NT [50] Plasma Sandwich ELISA N.S.
3-NT [9] Plasma Solid phase ELISA 3.12e200 nM (Detection range)
3-NT-containing proteins [71] Plasma Competitive ELISA 10 to 500 nM (Standard curve)
3-NT-modifed proteins [72] Plasma Competitive ELISA 10 mMe10 mM (Standard curve)
3-NT [26] Plasma and serum Sandwich ELISA 1.8 nmol/L (Sensitivity)
Protein bound 3-NT [69] Plasma and serum Indirect ELISA 1.82 ± 0.56 pmol/mg protein (LOD)
4.29 ± 1.56 pmol/mg protein (LOQ)
3-NT [9] Plasma and serum Competitive luminescence assay (CLIA) 1.68 nMe101 mM (Detection range)
3-NT [68] Plasma and sputum ELISA microarray N.S.
3-NT [36] Serum Sandwich ELISA N.S.
Protein bound 3-NT [58] Serum Sandwich ELISA 2 nM (LOD)
LOD, limit of detection; LOQ, limit of quantification; N.S.,not stated.
Table 3
Chromatographic techniques used based on samples characteristics.
Chromatographic technique Mobile phase Stationary phase Sample
Gas chromatography Gas Solid/liquid Gaseous sample (ordinary temperatures)
Samples that vaporise (when heated)
Liquid chromatography Liquid Solid/liquid Liquid samples
Solid samples (solvent-soluble)detection limit of 0.2 mM [77]. Variants of this method have been
used in several studies to determine 3-NT. Hitomi et al. [78] per-
formed an optimization of 3-NT separation process, showing that it
depends on the mobile phase used. Moreover, the retention time
depends on two factors, (i) the pH of the mobile phase, and (ii) the
concentration of acetonitrile. The retention time was prolonged by
a powerfully acidic mobile phase.
HPLC-UV detector. The HPLC-UV allows the detection of 3-NT as
free amino acid, and associated with peptides and proteins as well
[79]. Tyr and 3-NT have a maximum absorbance at 280 nm in so-
lution at pH 3.5. Additionally, 3-NT has a second absorbance at
357 nm. However, this second wavelength is more selective and,
therefore, more suitable for detection purposes. In basic solutions
(pH 9.5), 3-NT has a maximum absorbance at 430 nm [79,80]. The
main drawback of this method is the lack of selectivity and sensi-
tivity. HPLC coupled to ECD has the potential to be more selective
than HPLC-UV or HPLC-fluorescent methods [13].
HPLC-Diode Array Detector. Comparatively to UV detection,
DAD allows the simultaneous detection at different wavelengths
[81]. Although HPLC-DAD is the most commonly used method for
in vitro 3-NT analysis, it is not enough sensitive for in vivo quanti-
tative analysis [65]. Recently, Selzle et al. [82] developed a simple
and efficient HPLC-DAD method for the determination of the
nitration degree of small amounts of the birch pollen allergen Bet v
1. This method can be photometrically calibrated by the amino
acids Tyr and 3-NT without the need for nitrated protein standards.
The study also reported that this new method can be used in the
investigation of the reaction kinetics and mechanism of protein
nitration [82].
HPLC-fluorescence detection. Since 3-NT is not a fluorescent
compound, it can only be detected using a fluorescence detector
after structural modifications, such as the reaction of the amino
group of 3-NT with a suitable derivatizing reagent [80]. For
instance, Pourfarzam et al. [32] used 4-fluoro-7-nitrobenzo-2-oxa-
l,3-diazole (NBD-F) as derivatization reagent. This reagent has been
reported in several studies and the results obtained were compa-
rable among them [32]. The fluorescent dyes used in the derivati-
zation step of amino acids significantly improve the sensitivity and
specificity of detection. NBD-F has a 10-fold higher sensitivity thanortho-phthaldialdehyde (OPA) [56]. The limitation of this method is
that several fluorescent compounds are produced during the
derivatization process [80].
HPLC-Electrochemical detector. HPLC using ECD is relatively
low-cost and has sufficient sensitivity for the measurement of 3-NT
at moderately low basal levels found in most biological samples
from healthy individuals. These ECD-based methods have the po-
tential to be more selective than HPLC-UV or HPLC-fluorescence
methods, with a sensitivity about 100-fold greater [29].
The reproducibility of chromatogram signal intensity and
retention time of 3-NT are determined by the quality of the C18
column used, as well as the appropriate maintenance of the
electrochemical cell. Such reproducibility is ensured by (i)
routine washing of the column with methanol, (ii) ensuring that
potentials are not applied when the mobile phase is not flowing,
and (iii) periodic reconditioning of the electrode when a per-
formance loss is detected [29].
5.2.2. Liquid chromatography-mass spectrometry methods
One of the ways to overcome the limitations of HPLC is to couple
it with an MS. This combination is advantageous for robust and
unambiguous identification of compounds, especially when in the
MS/MS mode [13,83]. Analytical methods based on MS-
methodology are normally accepted as gold standards for the
analysis of endogenous substances in biological fluids, owing to
their high accuracy [1]. The advantage of this technique is that it
does not require sample derivatization to increase its volatility,
unlike gas chromatography-mass spectrometry (GC-MS), since it
increases the likelihood of artifacts formation [13,83].
Nevertheless, liquid chromatography-mass spectrometry (LC-
MS) does not offer the necessary selectivity for 3-NT measurement
in biological sample, especially in human plasma [13,83]. One way
to improve the selectivity and sensitivity for measurement is to use
HPLC Hypercarb columns in triple-stage quadrupole LCeESI (Elec-
trospray ionization) -MS/MS. The Hypercarb columns are
composed of porous spherical carbon particles and the separation is
based on the stronger retention time for polar compounds [13].
Chen & Chiu [84] developed a highly specific and accurate LC/
MS/MS assay that allows simultaneous analysis of protein-bound 3-
Table 4
Different HPLC-based methods used for the determination of 3-NT in biological samples.
Compound Sample Columna Eluents Flow
rate
(mL/
min)
Detection
method
LOD LOQ
for 3-NT
3-NT [24] Animal spleen tissues Microtech Scientific
C18
1.0  50; 5
50 mM H3PO4, 50 mM citric acid, 40 mg/L EDTA,
100mg/L octane sulfonic acid, 5%methanol (v/v) (pH
3.1 with KOH)
0.05 ECD N.S.
N.S.
3-NT residues in
protein [79]
Bovine serum albumin and ovalbumin Grace Vydac
2.1  250; 5
0.1% (v/v) TFA in water and ACN 0.3 DAD
280 and
357 nm
4.3 pmol
N.S.
3-NT, Tyr [64] Brain tissue Inertsil® ODS C18
4.6  250; 5
50 mM sodium acetate (pH 4.2), 10% methanol (v/v) 0.8 DAD
278 nm
6.7 nM
N.S.
Tyr and 3-NT [25] Gaseous nitrogen oxide species Inertsil ODS-2
4.6  250; 5
0.5% (v/v) acetic acid:methanol (29:1, v/v) 1.0 UVeVIS
detector
280 nm
N.S.
N.S.
3-NT, Tyr [56] Plasma Nova-Pak C18
3.9  150; 4
Mobile phase A: ACN and 0.02 M phosphate buffer
(pH 6.5; 90:10 v/v), 375 mL/L TFA, 5 mL/L 2-propanol
(pH ¼ 4.5)
Mobile phase B: ACN and 0.02 M phosphate buffer
(pH 6.5; 10:90 v/v), 500 mL/L TFA (pH 3.5)
1.0
(34 C)
UV
540 nm
0.5 nM
N.S.
3-NT [85] Plasma SD ODS
3.0  150; 5
100 mM phosphate buffer solution, 5% methanol (v/
v)
0.5
(25 C)
ECD <10 fmol
N.S.
Free 3-NT Assay
[32]
Plasma Nova-Pak C18
3.9  150; 4
Sodium phosphate buffer (0.1 M, pH 7.2), methanol
(52.5:47.5 v/v)
1.0 UV
470 and
540 nm
0.2 nM
0.6 nM
3-NT [73] Proteins from blood plasma Two ultrasphere
ODS
4.6  150; 3
4.6  46; 5
50 mM sodium acetate (pH 4.7), 5% methanol (v/v) 0.7 UV
280 nm
1 pmol
z400 pmol
3-NT [78] Rat plasma SC-50ODS
3.0  150; 5
200mMphosphate buffer containing 5mg/mL EDTA,
2% ACN
0.5 ECD N.S.
N.S.
Free 3-NT [58] Serum C18 reversed phase
column
4.6  250; 5
500 mM potassium phosphate buffer
(pH 3.5), 10% methanol (v/v)
0.8 UV
274 nm
0.20 nM
N.S.
3-NT [63] Sputum and saliva C18 reversed phase
column
3.0  150; 5
100 mM sodium phosphate buffer
(pH 5.0), 5% methanol (v/v)
0.5 ECD 10 fmol
N.S.
Tyr and 3-NT
metabolites [46]
Undifferentiated human
teratocarcinoma NT2 and rat
pheochromocytoma PC12 cell lines
Octadodecyl silica
gel reverse-phase
column
4.6  250; 5
0.1% TFA in ultra pure water (solvent A) and 100%
ACN (solvent B)
1.0 DAD
215, 275,
365 nm
N.S.
N.S.
3-NT, p-nitro-L-
phenylalanine,
and L-Tyr [59]
Urine Nucleosil 100-5 C18
4.0  250; 5
50 mM (NH4)2SO4 in water-methanol (95:5, v/v) (pH
5.5)
1.0 UV
276 nm
6 pmol
N.A.
ACN, acetonitrile; EDTA, ethylenediamine tetraacetic acid; TFA, trifluoroacetic acid; LOD, limit of detection; LOQ, limit of quantification; N.S.,not stated.
a Column dimensions in the following order: internal diameter (in mm) x length (in mm); particle size (in mm).NT and 3-bromotyrosine (3-BT) in human urine. This proteins
function as non-invasive biomarkers for in vivo PTN and
bromination.
Table 5 describes several liquid chromatography-based
methods/protocols for determination of 3-NT in biological sam-
ples that have been published over the last year.
5.2.3. Gas chromatography-mass spectrometry methods
GC-MS methodology is used for the analysis of volatile and
thermally stable small molecules [13]. When molecules to be ana-
lysed, such as amino acids, do not meet these features, a further
derivatization step is required. In this sense, analysis of 3-NT by this
methodology requires prior chemical derivatization and/or modi-
fication of the functional groups (i.e., p-OH, a-NH2, and COOH) to
increase volatility and thermal stability (i.e., reduction of the aro-
matic NO2 group). In addition, derivatization improves GC and MS
behaviour of 3-NT [83]. Derivatization, however, often accounts for
3-NT artifact formation, which is may be responsible for high
variation of basal plasmatic 3-NT levels [1]. Nevertheless, GC-
tandem MS is described as a methodology that allows the accu-
rate quantification of free 3-NT in humanplasma at basal levels. GC-tandem MS is more accurate than GC-MS [1,59]. Table 6 summa-
rises different gas chromatography-based methods for determina-
tion of 3-NT in biological samples.
The GC-MS and GC-MS/MS methods for the analysis of 3-NT
involve the preparation of perfluorinated derivatives. Per-
fluorinated compounds are strong electron-capturing species, thus
offering assays of particularly high sensitivity [83].
Gaut et al. [87] reported that GCeMS was 100-fold more
sensitive than LCetandem MS for the analysis of 3-NT. The major
drawback of this method is that 3-NT is not suitably separated
from Tyr, nitrite and nitrate prior to GCeMS analysis or deriva-
tization. Such separation could potentially be achieved, for
instance, by HPLC [14].
In the study performed by S€oderling et al. [54], the derivati-
zation method used was based on the reduction of the nitro
group of 3-NT by dithionite, heptafluorobutyric acylation and
subsequent methyl derivatization. Their results demonstrated
excellent GC and MS properties, namely low background and a
favourable fragmentation pattern [54].
In fact, the major strategies used to avoid artifacts formation
are (i) isolation of 3-NT by SPE and HPLC; (ii) reduction of 3-NT to
Table 5
Different liquid chromatography-based methods used for the determination of 3-NT in biological samples.
Compound Sample Columna Eluents Flow rate Detection
method
LOD LOQ for
3-NT
Free amino acid and
protein 3-NT [57]
Biological
fluids
Immunoaffinity
column: Targa
4.6  30
C18 reversed-phase
column: Betasil
2.1  100; 5
Immunoaffinity column: 1% formic acid
C18 reversed-phase column: 100% 10 mM ammonium
acetate acetonitrile
Immunoaffinity
column: 1 mL/min
C18 reversed-phase
column: 0.3 mL/min
Immunoaffinity
LCeMS/MS
5 pg/mL
(22.1 pM)
5 pg/mL
(Lower
LOQ)
3-NT [15] Microglial
Cell Lysate
EASY-Spray™
250  0.075; 2
0.1% formic acid in water (mobile phase A) and 0.1%
formic acid in ACN (mobile phase solvent B)
350 nL/min LC-MS/MS N.S.
N.S.
Free 3-NT [86] Plasma Altima HP
100  2.1 mm; 3
Kinetex
100  2.1; 2.6
0.01% acetic acid in ultrapure water (mobile phase A)
þ
0.01% acetic acid in ACN (mobile phase B)
0.2 mL/min LC-MS/MS 0.034 nM
0.112 nM
3-chlorotyrosine, 3-
BT, and 3-NT [87]
Plasma C18 reversed phase
column Zorbax
1.0  150; 5
Methanol/water/acetic acid (4/95/1,v/v/v, pH 3e solvent
A)
þ
methanol/water/acetic acid (95/4/1, v/v/v, pH ¼ 3.2
-solvent B)
0.05 mL/min LCeMS/MS 3.2 fmol
N.S.
3-NT [88] Plasma and
Urine
HypercarbTMc
2.1  50; 5
0.1% TFA with a linear
gradient of 10e50% acetonitrile
0.2 mL/min LC-MS/MS 0.022 pmol
N.S.
3-NT and 3-BT [84] Urine Reversed phase C18
column
2.0  150; 5
0.01% formic acid (pH 3.2) to 25% methanol in 0.01%
formic acid
0.2 mL/min LCeESI/MS/MS 44 fmol
N.S.
3-NT, 3-BT,
Dibromotyrosine
[89]
Urine ODS-SR
2  150; 5
0.05% formic acid/CH3CN (95:5) Not stated LC/MS/MS 1 nM
N.S.
ACN, acetonitrile; TFA, trifluoroacetic acid; LOD, limit of detection; LOQ, limit of quantification; N.S., not stated.
a Column dimensions in the following order: internal diameter (in mm) x length (in mm); particle size (in mm).
Table 6
Different gas chromatography-based methods used for the determination of 3-NT in biological samples.
Compound Sample Columna Eluents Detection
method
LOD LOQ for
3-NT
3-NT [60] CSF DB-1 MS
column
15  0.32;
0.25
Helium (3psi); Methane (750e800 Pa) GCeMS/MS N.S.
N.S.
Free 3-NT [62] Exhaled breath
condensate (EBC)
DB5-MS
column
30  0.25;
0.25
Helium (38 kPa); Methane (0.97e0.99 kPa) GC/NICI/
tandem MS
0.56 pM
1.70 pM
Protein-associated 3-NT and 3-
nitrotyrosinoalbumin [55]
Plasma Optima 5-
MS
30  0.25;
0.25
Helium (55 kPa); Methane (530 Pa) and Argon (0.27 Pa) GCeMS/MS N.S.
N.S.
3-NT [54] Plasma DB5-MS
column
30  0.25;
0.25
Helium (41 kPa); Methane (0.27e1.1 kPa) GCeMS/MS 0.03 nM
0.3 nM
3-NT [59] Urine Optima 5-
MS
30  0.25;
0.25
Helium (55 kPa); Methane (530 Pa) and Argon (0.27 Pa
collision pressure)
GCeMS/MS 4 amol
125 pM
a Column dimensions in the following order: internal diameter (in m) x length (in mm); particle size (in mm), LOD, limit of detection; LOQ, limit of quantification; N.S., not
stated.3-amimotyrosine before sample derivatization, thus artifactual
nitration of Tyr does not influence the measurement; (iii) use of
high concentrations of reactive aromatic compounds (i.e.,
phenol) to capture nitrosating species; and (iv) quantification
of artifactual 3-NT formation, by incorporating stable-isotope
labelled Tyr (e.g., 13 C6 -Tyr) into each sample [83].
Overall, the main disadvantage of using chromatographic
methods is that they involve time-consuming sample prepara-
tion procedures [69].6. Conclusions
As previously stated, nitration of proteins is a common process
that occurs under physiological conditions. On the other hand, a
significant increase in the extent of this process, induced by an
increased nitrative stress state, has been associated with a wide
range of diseases.
3-NT has been pointed out as a potential biological tool for the
therapeutic monitoring of this process. However, PTN is typically a
low-yield process, thus it requires sensitive analyticalmethods for its
quantification. Regarding this, the quantification of 3-NT poses some
challenges, namely: (i) endogenous levels are extremely low, andnear
the limits of detection/quantitation formost of the currently available
analytical methods; (ii) 3-NT must be detected and quantified in the
presence of a vast excess of Tyr, thus requiring high selective method
(avoiding interferences fromother closely relatedmolecules; and (iii)
changes in 3-NT levels may be very slight.
In summary, a wide range of methods for 3-NT detection and
quantification has been developed during the last years, all of them
presenting positive and negative aspects. Regarding ELISA-based
methods, and despite being the least time-consuming and straight-
forward methods, it has become clear that they do not provide the
most accurate results. On the other hand, and in relation to chro-
matographic methods, they seem to be very accurate, showing very
goodsensibilityandspecificity.GC-basedmethodsexhibit thehighest
sensibility in the quantification of 3-NT. However, and owing to 3-NT
chemical properties, a derivatization step prior analysis is required,
which ends up being time-consuming for the analyst. Moreover,
derivatization reactions often induce artifacts formation, which may
further influence thefinal analysis. Conversely, HPLC does not require
such derivatization step, despite being not as accurate as GC.
Regarding this matter, and in order to improve both sensitivity and
specificity of HPLC-based methods, further optimization of the pro-
tocols that have been described is clearly needed.
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